PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare Announces Norwegian Medicines Agency Approval of Sonazoid™ to Detect Liver Lesions - GE Healthcare announced the Norwegian Medicines Agency’s (NOMA) approval of Sonazoid™ (powder and solvent for dispersion for injection), a contrast agent for use in ultrasound imaging of focal liver lesions
GE Healthcare Announces Norwegian Medicines Agency Approval of Sonazoid™ to Detect Liver Lesions

 

NewswireToday - /newswire/ - Oslo, Norway, 2014/06/11 - GE Healthcare announced the Norwegian Medicines Agency’s (NOMA) approval of Sonazoid™ (powder and solvent for dispersion for injection), a contrast agent for use in ultrasound imaging of focal liver lesions. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The approval is based on clinical studies which showed that Sonazoid significantly improved the visualization of liver lesions during ultrasonography, and may help clinicians better determine whether or not a tumor is malignant or benign.[i]

“Sonazoid is an important tool to improve the current visualization methods to evaluate patients with liver lesions,” said Dr. Knut Brabrand, senior consultant in radiology, Oslo University Hospital, Rikshospitalet. “One important feature of Sonazoid is its longer contrast effect which I believe may improve the detection of liver tumors. Also, the ability to differentiate malignant tumors from benign tumors and primary tumors from metastatic tumors is critical to determine the appropriate treatment to help improve a patient’s prognosis.”

Clinical Trial Results Supporting NOMA Approval
The primary clinical trial results from Japan supporting approval were published in the American Journal of Roentgenology and showed how the accuracy of Sonazoid-enhanced ultrasound in characterizing focal liver lesions as malignant or benign was significantly greater than the accuracy of both non-contrast ultrasound and dynamic CT.1 Other studies have shown that the efficiency of Sonazoid-enhanced ultrasound in detecting liver lesions was significantly higher than that of non-contrast ultrasound. In particular, Sonazoid-enhanced ultrasound was superior to dynamic CT in detecting metastatic liver lesions measuring 1 cm or smaller, indicating that Sonazoid-enhanced ultrasound may be a sensitive tool for following up colorectal cancer patients after primary treatment.[ii], [iii] Sonazoid-enhanced ultrasound has been shown to be a well-tolerated procedure in more than 2,500 patients.[iv]

“The approval of Sonazoid underscores GE Healthcare’s commitment to provide medical imaging solutions that help physicians deliver better care to more people,” said Jan Makela, General Manager of Core Imaging. “We expect that Sonazoid will make a significant difference in the way Norwegian liver cancer patients are evaluated and treated.”

While the prevalence of primary liver cancer is low in Norway, according the World Cancer Research Fund International, the incidence of colon cancer is among the highest in the world. Norway is ranked 6th in the world for prevalence of colon cancer.[v] Approximately 60 to 70 percent of people with colorectal cancer eventually develop a liver tumor. In fact, the liver is the only site of metastasis in up to 35 percent of patients with metastatic colorectal cancer.[vi]

About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

[i] Moriyasu F, Itoh K. Efficacy of Perflubutane Microbubble Enhanced Ultrasound in the Characterization and Detection of Focal Liver Lesions:

Phase 3 Multicenter Clinical Trial. AJR 2009; 193:86 95.

[ii] Kudo et al. 2011.
[iii] Kudo et al. 2010
[iv] Sonazoid Summary of Product Characteristics, March 2014
[v] World Cancer Research Fund International wcrf.org/. (accessed 3/12/14)
[vi] Tomlinson JS, Jamigan WR, DeMatteo RP, et al. J, Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of Clinical Oncology 2007 25(29): 4575-9. Available at ncbi.nlm.nih.gov/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare Announces Norwegian Medicines Agency Approval of Sonazoid™ to Detect Liver Lesions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE News Center | Sonazoid™
Publisher Contact: Scott Lerman - GE.com 
609-514-6346 / 609-937-9253 (mobile) Scott.Lerman[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)